glibornuride 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antihyperglycaemics | 1298 | 26944-48-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
was MH 1975-92 (see under SULFONYLUREA COMPOUNDS 1975-90); use SULFONYLUREA COMPOUNDS to search GLIBORNURIDE 1975-92; an oral, sulfonylurea hypoglycemic agent which stimulates insulin secretion
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 38 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.20 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 0.50 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 2.92 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| Vd (Volume of distribution) | 0.27 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 0.34 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 9.20 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 1, 1969 | YEAR INTRODUCED |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A10BB04 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Sulfonylureas |
| MeSH PA | D007004 | Hypoglycemic Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Diabetes mellitus type 2 | indication | 44054006 | DOID:9352 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 5.65 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sulfonylurea receptor 1, Kir6.2 | Ion channel | BLOCKER | Kd | 7.05 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
| Sulfonylurea receptor 2, Kir6.2 | Ion channel | BLOCKER | Ki | 5.17 | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| D02427 | KEGG_DRUG |
| C0350998 | UMLSCUI |
| CHEBI:135545 | CHEBI |
| CHEMBL529888 | ChEMBL_ID |
| DB08962 | DRUGBANK_ID |
| C073323 | MESH_SUPPLEMENTAL_RECORD_UI |
| 12818200 | PUBCHEM_CID |
| 2751 | INN_ID |
| VP83E7434R | UNII |
| 102846 | RXNORM |
| 005328 | NDDF |
| 325235002 | SNOMEDCT_US |
| 419384001 | SNOMEDCT_US |
Pharmaceutical products:
None